SELLAS Life Sciences Group, Inc. Common Stock
$11.53
-$0.13 (-1.11%)
$11.23Day Range$11.80
Key Statistics
Market Cap
$2.35B
Shares Outstanding
201.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 12, 2008
Round Lot
100
Locale
US
Trading Data
Day Open
$11.30
Day High
$11.80
Day Low
$11.23
Volume
4.81M
VWAP
$11.48
Prev Close
$11.66
Transactions
--
Acc. Volume
--
About SELLAS Life Sciences Group, Inc. Common Stock
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
PHARMACEUTICAL PREPARATIONSSIC 283413 employees7 TIMES SQUARE, NEW YORK, NY, 10036(646) 200-5278IPO Mar 12, 2008US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001390478
- Composite FIGI
- BBG000VC77H7
- Share Class FIGI
- BBG001T223C9
- Ticker Root
- SLS
- SIC Code
- 2834
About SELLAS Life Sciences Group, Inc. Common Stock (SLS) Stock
SELLAS Life Sciences Group, Inc. Common Stock (SLS) closed the 2026-09-17 session at $11.53, down 1.11% versus the previous close (-0.13). The stock opened at $11.30 and traded between $11.23 and $11.80 during that session. Session trading volume was 4.8M shares. The volume-weighted average price (VWAP) is $11.48.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
SELLAS Life Sciences Group, Inc. Common Stock has a market capitalization of $2.35 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SLS is listed on the XNAS exchange. The company employs approximately 13 people. SELLAS Life Sciences Group, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2008-03-12.
On this page you can find market SLS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.